Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Immunotherapy with differentiated, adult, autologous, peripheral blood T lymphocytes, expanded and transduced (genetically modified) using a lentiviral vector to express a chimeric receptor with anti-CD30 specificity associated with costimulatory sequences 4-1-BB and CD3z in patients with Classic Hodgkin lymphoma and non-Hodgkin T lymphoma with CD30 expression.

Proposed period of release:
01/01/2019 to 31/12/2021

Name of the Institute(s) or Company(ies)
Fundació Institut de Recerca de l’Hospital de la
Santa Creu i Sant Pau, C/ Sant Quinti, 77-79. 08041. Barcelona;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
Other: mammal

Identity of the GMO:
Autologous T lymphocytes transduced with a lentivirus to express a chimeric (murine / human)
antigen receptor (CAR) directed against CD30 (T-CAR30 cells). Homo sapiens.

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known